Follow one topic of conversation at a time
Two new treatments with indication for CAPS
Choose a language: EN FR ALL-
rdc-team | Medication, Treatment & Care, Muckle-Wells, NOMID, FCAS | 2 months ago | written in English Two new treatments with indication for CAPSInformation relating to two new treatments with an indication for the treatment of CAPS syndromes and which have recently received their Marketing Authorisation from the European Medecines Agency are available at the following URLs:
For Canakinumab (Ilaris):
www.ema.europa.eu/humandocs/Humans/EPAR/il...For Rilonacept (Arcalyst):
www.ema.europa.eu/humandocs/Humans/EPAR/ar...Access to these treatments will not immediately occur in each of the European Member States - this can take time. Best consult with your doctor or specialist.
In the USA the FDA provide information here:
For Canakinumab (Ilaris):
www.accessdata.fda.gov/scripts/cder/drugsa...For Rilonacept (Arcalyst):
www.accessdata.fda.gov/scripts/cder/drugsa...Finally just a word to say that the aim of this post is simply to provide information. The decision to take any of these treatments should be done in consultation with a medical professional.
One reply to the topic-
rdc-team 2 months ago | written in EnglishFurther information on Canakinumab (Ilaris®) in French published by the French Regulatory Authority - Haute Autorité de Santé is available at the following link:
bit.ly/ilarisfr
This document explains the conclusions from the 3 phases of clinical trials, compares the treatment to other available (prescription and off-lable) treatments for each of the CAPS syndromes and details the level of reimbursement in France to patients.
-